Search Within

Heiko Schoder

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (75)
  2. Meeting Abstract (63)
  3. Review (6)
  4. Editorial (3)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Molecular Imaging and Therapy Service (153)
  2. Radiology, Department of (153)
  3. Sloan Kettering Institute Postdocs (153)
  4. Department of Medicine (92)
  5. Epidemiology and Biostatistics (65)
  6. Biostatistics Service (61)

More Groups

People
  1. John Humm (41)
  2. Maria Palomba (32)
  3. Milan Grkovski (31)
  4. Gilles Salles (30)
  5. Laure Michaud (29)
  6. Audrey Mauguen (28)

More People

Years
  1. 2025 (10)
  2. 2024 (22)
  3. 2023 (27)
  4. 2022 (18)
  5. 2021 (24)
  6. 2020 (16)

More Years

Publications
  1. Journal of Nuclear Medicine (33)
  2. European Journal of Nuclear Medicine and Molecular Imaging (19)
  3. Blood (17)
  4. International Journal of Radiation Oncology, Biology, Physics (8)
  5. Journal of Clinical Oncology (8)
  6. Clinical Cancer Research (4)

More Publications

Publishers
  1. Society of Nuclear Medicine (33)
  2. Springer (28)
  3. American Society of Hematology (19)
  4. Elsevier Inc. (14)
  5. American Society of Clinical Oncology (8)
  6. American Association for Cancer Research (7)

More Publishers

Results (153)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The quest for an accurate functional tumor volume with (68)Ga-DOTATATE PET/CT
    Journal Article

    Reddy, R. P.; Schmidtlein, C. R.; Giancipoli, R. G.; Mauguen, A.; LaFontaine, D.; Schoder, H.; Bodei, L.
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated (WD) high-grade (HG) neuroendocrine tumors (NETs) to (177)Lu-DOTATATE
    Meeting Abstract

    Coffman, K.; Bodei, L.; Le, T.; Choi, Y.; Chou, J.; Capanu, M.; Dunphy, M.; Fox, J.; Grewal, R.; Reddy, R.; more...
    Pancreas (2022)

    Fulltext@MSK | Save
  • Blood-based genomic assessment of clinical efficacy and toxicity of (177)Lu-DOTATATE of neuroendocrine tumors
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, K. G.; Krebs, S.; Reidy-Lagunes, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schöder, H.
    Pancreas (2022)

    Fulltext@MSK | Save
  • Predicting F-18 FMISO PET hypoxia measurements from F-18 FDG PET scan using a generative adversarial network
    Meeting Abstract

    Zhao, W.; Grkovski, M.; Lee, N.; Schoder, H.; Humm, J.; Veeraraghavan, H.; Deasy, J.
    Medical Physics (2022)

    Fulltext@MSK | Save
  • Radiotheranostics in oncology: Current challenges and emerging opportunities
    Review

    Bodei, L.; Herrmann, K.; Schöder, H.; Scott, A. M.; Lewis, J. S.
    Nature Reviews Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save